CZ151599A3 - Způsob krystalizace draselné soli losartanu - Google Patents

Způsob krystalizace draselné soli losartanu

Info

Publication number
CZ151599A3
CZ151599A3 CZ991515A CZ151599A CZ151599A3 CZ 151599 A3 CZ151599 A3 CZ 151599A3 CZ 991515 A CZ991515 A CZ 991515A CZ 151599 A CZ151599 A CZ 151599A CZ 151599 A3 CZ151599 A3 CZ 151599A3
Authority
CZ
Czechia
Prior art keywords
potassium salt
crystallization process
losartan potassium
losartan
crystallization
Prior art date
Application number
CZ991515A
Other languages
English (en)
Other versions
CZ291672B6 (cs
Inventor
Patrick Breen
Erik A. Dienemann
Albert D. Epstein
Karen A. Larson
Michael T. Kennedy
Hari Mahadevan
Original Assignee
Merck And Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625804.1A external-priority patent/GB9625804D0/en
Application filed by Merck And Co., Inc. filed Critical Merck And Co., Inc.
Publication of CZ151599A3 publication Critical patent/CZ151599A3/cs
Publication of CZ291672B6 publication Critical patent/CZ291672B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CZ19991515A 1996-10-29 1997-10-24 Způsob krystalizace draselné soli losartanu CZ291672B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2932696P 1996-10-29 1996-10-29
GBGB9625804.1A GB9625804D0 (en) 1996-12-12 1996-12-12 Process for the crystallization of losartan

Publications (2)

Publication Number Publication Date
CZ151599A3 true CZ151599A3 (cs) 1999-10-13
CZ291672B6 CZ291672B6 (cs) 2003-04-16

Family

ID=26310606

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19991515A CZ291672B6 (cs) 1996-10-29 1997-10-24 Způsob krystalizace draselné soli losartanu

Country Status (18)

Country Link
US (1) US5859258A (cs)
EP (1) EP0937068B1 (cs)
JP (1) JP3249827B2 (cs)
CN (1) CN1101393C (cs)
AR (1) AR010256A1 (cs)
AT (1) ATE214388T1 (cs)
AU (1) AU5089898A (cs)
BR (1) BR9712390A (cs)
CZ (1) CZ291672B6 (cs)
DE (1) DE69711068T2 (cs)
DK (1) DK0937068T3 (cs)
EA (1) EA001046B1 (cs)
ES (1) ES2173433T3 (cs)
HR (1) HRP970565B1 (cs)
PT (1) PT937068E (cs)
SK (1) SK282875B6 (cs)
TW (1) TW411338B (cs)
WO (1) WO1998018787A1 (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226372A (ja) 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
JP2002080354A (ja) * 2000-09-05 2002-03-19 Kao Corp 血圧降下剤組成物
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
WO2002094816A1 (en) * 2001-05-18 2002-11-28 Aurobindo Pharma Limited Process for the crystallization of losartan potassium
AU2002334987A1 (en) * 2001-10-15 2003-04-28 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
WO2003035039A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
SI1474417T1 (sl) 2002-04-29 2006-08-31 Teva Pharma Postopek za pripravo lozartana in kalijevega lozartana
US20040097568A1 (en) * 2002-07-29 2004-05-20 Dr. Reddy's Laboratories Limited Crystalline form of losartan potassium
AU2003284262A1 (en) * 2002-10-17 2004-05-04 Teva Pharmaceutical Industries Ltd. Process for preparing losartan potassium with improved flowability
WO2004039352A2 (en) * 2002-10-31 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of losartan potassium
DE602004029982D1 (de) * 2003-01-30 2010-12-23 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
WO2004076442A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphs of losartan
US7345071B2 (en) 2003-05-07 2008-03-18 Ipca Laboratories Limited Process for the synthesis of Losartan potassium
ITMI20032472A1 (it) * 2003-12-16 2005-06-17 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di losartan potassio cristallino
WO2005066158A2 (en) * 2004-01-06 2005-07-21 Ipca Laboratories Limited An improved process for the synthesis of losartan potassium
BRPI0512379A (pt) * 2004-06-23 2008-03-11 Solvay Pharm Gmbh composições farmacêuticas compreendendo inibidores de nep, inibidores do sistema de produção de endotelina endógena e antagonista do receptor at1
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
ITMI20050551A1 (it) * 2005-04-01 2006-10-02 Dipharma Spa Forma cristallina alfa di losartan potassio
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
SK280887B6 (sk) 1991-11-18 2000-09-12 E. I. Du Pont De Nemours And Company Spôsob výroby tetrazolylbifenylových zlúčenín a medziprodukty tohto spôsobu
US5206374A (en) * 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
US5130439A (en) * 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
US5310928A (en) * 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
AU685898B2 (en) * 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan

Also Published As

Publication number Publication date
EP0937068B1 (en) 2002-03-13
JP3249827B2 (ja) 2002-01-21
AU5089898A (en) 1998-05-22
BR9712390A (pt) 1999-08-31
CN1101393C (zh) 2003-02-12
JP2000504343A (ja) 2000-04-11
HRP970565B1 (en) 2003-02-28
DE69711068T2 (de) 2002-09-12
US5859258A (en) 1999-01-12
DK0937068T3 (da) 2002-05-21
CZ291672B6 (cs) 2003-04-16
ES2173433T3 (es) 2002-10-16
WO1998018787A1 (en) 1998-05-07
EA001046B1 (ru) 2000-08-28
EA199900427A1 (ru) 1999-10-28
ATE214388T1 (de) 2002-03-15
PT937068E (pt) 2002-07-31
SK282875B6 (sk) 2003-01-09
CN1241186A (zh) 2000-01-12
AR010256A1 (es) 2000-06-07
SK57099A3 (en) 2000-02-14
HRP970565A2 (en) 1998-08-31
EP0937068A1 (en) 1999-08-25
DE69711068D1 (de) 2002-04-18
TW411338B (en) 2000-11-11

Similar Documents

Publication Publication Date Title
CZ151599A3 (cs) Způsob krystalizace draselné soli losartanu
EG23874A (en) Process for the preparation of a magnesium salt ofa substituted sulphinyle heterocycle
HU9603081D0 (en) Process for selective synthesis of sylil-alkyl-disulfides
SI1149090T1 (en) Novel crystalline form of the potassium salt of (s)-omeprazole
PL346544A1 (en) Crystalline forms of eto2
GB2280436B (en) Process for the crystallization of lopamidol
GB9908550D0 (en) Process for the purification of brines
SG65610A1 (en) Process for the preparation of lactams
GB2318350B (en) Process for purification of hydrochlorofluoroethanes
HUP0004030A3 (en) Process for the purification of aspartame derivative
HUP9702444A3 (en) Selective process for the deacylation of acylated compounds
PL339904A1 (en) Method of synthesising intermediate chloropurin compounds
IL113104A0 (en) Process for the production of granulated potassium chloride
IL127415A (en) Process for preparing potassium clavulanate
PL322111A1 (en) Method of obtaining locarbeph monohydrate
HUP0003024A3 (en) Method for producing nitroguanidine derivatives and the novel starting compounds
GB2298861B (en) Process for producing improved crystals of 3-amino-2-hydroxyacetophenone salt
EP0703214A3 (en) Process for the production of anhydrous phenylalanine crystals
IL131765A0 (en) Process for the purification of substituted p-nitrodiphenylethers
GB9625804D0 (en) Process for the crystallization of losartan
PL323143A1 (en) Pyrolydinylmethylindole salt
HU9701426D0 (en) Process for the preparation of acid chloride compounds
HUP0102089A3 (en) Process for the preparation of nitroguanidine derivatives
AU1455895A (en) Use of n-acyl lactams as crystallisation inhibitors
IL114313A0 (en) Use of rosins as crystallization inhibitors

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20101024